Composition for therapeutic and cosmetic botulinum toxin
View Patent ↗This invention relates to a composition of botulinum based pharmaceuticals used for therapeutic and cosmetic treatment. This invention offers an improvement on the prior art by eliminating the potential of blood-borne contamination with botulinum based pharmaceuticals. Recombinant serum albumin is taught for use in the place of human serum albumin as a stabilizing or enhancing agent.
1. A pharmaceutical composition comprising a botulinum neurotoxin and a recombinant serum albumin at a concentration greater than 2.0 mg/cc per 20 mouse LD 50 units of neurotoxin.
2. The pharmaceutical composition of claim 1 , wherein the neurotoxin is selected from the group consisting of immunotypes A, B, C, D, E, F, and G.
3. The pharmaceutical composition of claim 1 , wherein the neurotoxin is immunotype A.
4. The pharmaceutical composition of claim 1 , wherein the recombinant serum albumin is recombinantly produced in yeast.
5. The pharmaceutical composition of claim 4 , wherein the yeast is Saccharomyces cerevisiae or Pichia pastoris.
6. The pharmaceutical composition of claim 1 , wherein the botulinum neurotoxin has a specific activity which exceeds 20 mouse LD 50 units per nanogram of neurotoxin.
7. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition contains no human blood product.
8. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition contains no human blood product and said botulinum toxin is immunotype A.
9. The pharmaceutical composition of claim 1 , wherein said recombinant serum albumin is recombinant human serum albumin.
10. A pharmaceutical composition comprising a botulinum neurotoxin and a recombinant serum albumin at a concentration greater than 0.5 mg/cc per 5 mouse LD 50 units of neurotoxin.
11. The pharmaceutical composition of claim 10 , wherein the neurotoxin is selected from the group consisting of immunotypes A, B, C, D, E, F, and G.
12. The pharmaceutical composition of claim 10 , wherein the neurotoxin is immunotype A.
13. The pharmaceutical composition of claim 10 , wherein the recombinant serum albumin is recombinantly produced in yeast.
14. The pharmaceutical composition of claim 13 , wherein the yeast is Saccharomyces cerevisiae or Pichia pastoris.
15. The pharmaceutical composition of claim 10 , wherein the botulinum neurotoxin has a specific activity which exceeds 20 mouse LD 50 units per nanogram of neurotoxin.
16. The pharmaceutical composition of claim 10 , wherein said pharmaceutical composition contains no human blood product.
17. The pharmaceutical composition of claim 10 , wherein said pharmaceutical composition contains no human blood product and said botulinum toxin is immunotype A.
18. The pharmaceutical composition of claim 10 , wherein said recombinant serum albumin is recombinant human serum albumin.